ClinicalTrials.gg
CompletedNCT01110356PreferUpdated Nov 15, 2012

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

A Phase 4 interventional study of Ferinject and Saline in Iron Deficiency, sponsored by Vifor Pharma. Completed at 1 site in Austria. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-15.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Enrollment
13th of 40
294 · median 134
Started
2010
with 1 other
Phase 4
18 of 40
6 open now
Registered
5th of 40
by date
Lead sponsor
8 of 40
Vifor Pharma

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 13th largest by enrollment, is one of 2 that started in 2010, is one of 18 in phase 4, and was the 5th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.

03

Conditions studied

  • Iron Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to study specific procedures.
  • Premenopausal, regularly menstruating women.
  • Age ≥18 years.
  • Body weight between 50 and 90 kg.
  • ≥115 g/L.
  • Iron deficiency at screening defined as follows:
  • S-ferritin level \<50 ng/mL, AND, TfS \<20%, OR,
  • S-ferritin level \<15 ng/mL.
  • Serum C-reactive protein:
  • \<5 mg/L if not on oral , OR,
  • \<20 mg/L if use of oral contraception.
  • Minimum total score of 5 on the Piper Fatigue Scale (PFS) (mean of items 2 to 23).
  • Negative pregnancy test (serum human chorionic gonadotropin (hCG) at screening.
  • Normal levels of vitamin B12 and folic acid at screening.
  • Adequate contraception during the study period and for 1 month following study completion.
  • Availability and willingness to complete all study visits and procedures per protocol.

Exclusion criteria

Exclusion Criteria:

  • level \<115 g/L.
  • Haemoglobinopathy.
  • Haemochromatose.
  • Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2).
  • Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction ( (AST); alanine aminotransferase (ALT) >3-fold upper limit), angina (Class IV).
  • Known /acquired immunodeficiency syndrome, virus or virus infection.
  • Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease).
  • Documented history of level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea.
  • Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness).
  • Important recent weight loss (>10% within the past month).
  • Body weight \<50 kg or >90 kg.
  • Thyroid dysfunction, thyroid stimulating hormone >4 μU/mL.
  • Intake of iron preparations 4 weeks prior to screening.
  • Use of gestagens e.g., Implanon, Mirena, Depo-Provera for menstruation repression (see Section 7.7, Prohibited Therapy or Concomitant Treatment, page 35).
  • Known to FCM or to any other iron preparation.
  • Pregnancy (positive hCG test at screening) or breast feeding.
  • Participation in any other interventional trial within 4 weeks prior to screening.
  • Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator's opinion.
  • Subject is not using adequate precautions during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner.
  • Subject previously has entered this study.
  • Subject will not be available for follow-up assessments.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    Ferinject

    Drug: Ferinject

  • Placebo comparator
    Saline

    Other: Saline

Interventions

  • Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.

  • OtherSaline

    Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of a single intravenous (IV) administration of FCM (1,000 mg) compared with placebo in improving fatigue symptoms in IDNA women of child bearing age.

    Time frame: Day 56

Secondary outcomes

  1. To compare efficacy of a single IV application of FCM with that of placebo on change of iron status on Day 56 (i.e., proportion of subjects with haemoglobin (Hb) ≥12 g/dL; serum-ferritin (s-ferritin) ≥50 ng/mL; transferrin saturation (TfS) >20%).

    Time frame: Day 56

  2. To determine the relationship between change in iron status (s-ferritin and TfS) and improvement of fatigue symptoms.

    Time frame: Day 56

07

Study locations

1 site
  • Universitätsklinik für Frauenheilkunde
    Vienna, 1090, Austria
08

References and documents

Publications

  • Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One. 2014 Apr 21;9(4):e94217. doi: 10.1371/journal.pone.0094217. eCollection 2014. PubMed 24751822 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Oct 2011 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 26, 2010
Start
Jun 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2012
Last update
Nov 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01110356
Lead sponsor
Vifor Pharma
Collaborators
SGS S.A.
Responsible party
Sponsor
First posted
Apr 26, 2010
Start date
Jun 2010
Primary completion
Oct 2011
Completion
Oct 2012
Last update
Nov 15, 2012

Study contacts

Bernard Favrat
principal investigator · Quartier UNIL-CHUV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion